Immuneering Corp. Class A (IMRX)
NASDAQ:IMRX
Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.56
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.56
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.66 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)1.83M
Market Cap
$271.08M
Enterprise Value-$43.38B
Total Cash (Recent Filing)$156.69M
Total Debt (Recent Filing)$3.73B
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding64,697,230
10 Day Avg. Volume2,421,235
30 Day Avg. Volume1,830,739
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap-160.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit49.02K
Enterprise Value/Ebitda737.10
Forecast
1Y Price Target
$13.75Price Target Upside147.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary AI-driven Discovery PlatformImmuneering’s proprietary computational biology and AI-driven platform is a durable competitive asset that can systematically identify and optimize small-molecule candidates. Over months this supports repeatable pipeline generation, improves R&D efficiency, and can lower discovery risk versus traditional approaches.
Advancing Atebimetinib To Pivotal Phase 3Positive Phase 2a outcomes with a defined plan for a mid-2026 Phase 3 start and a mid-2028 topline create a clear, multi-year clinical development pathway. This progression materially de-risks the lead program relative to earlier stages and positions the company for potential partnerships or regulatory milestones.
Low Financial LeverageVery low debt reduces solvency and interest-rate risks, preserving financial flexibility while the company advances late-stage trials. For a development-stage biotech, minimal leverage lowers the probability of near-term distress and provides optionality when negotiating partnerships or future financings.
Bears Say
No Meaningful Revenue BaseThe company has effectively no operating revenue, leaving its business model dependent on future commercialization or partner deals. Without recurring sales, management cannot rely on operating cash flow to fund R&D, making long-term sustainability contingent on successful trials or external capital.
Persistent Cash Burn And Weak Cash GenerationOperating and free cash flow have been consistently negative, producing material funding needs. This structural cash burn creates recurrent dilution and financing risk, constraining strategic flexibility and making execution dependent on successful capital raising or partnership timelines over the next 2–3 years.
Binary Clinical And Regulatory DependenceThe company’s long-term prospects hinge on the Phase 3 outcome for atebimetinib and subsequent regulatory progress. Late-stage clinical failure or delayed readouts would materially impair value creation, reduce partner interest, and exacerbate financing needs—a durable program-level binary risk.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $1.66 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $271.08M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Aug 12, 2026 which is in 56 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.042.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.27.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,230 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 0.389%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (147.30% Upside)
$13.75 (147.30% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 181.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
120.52%
12-Months-Change
Fundamentals
Return on Equity
-0.11%
Trailing 12-Months
Asset Growth
323.84%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$13.75
▲(147.30% Upside)
Technical Analysis
Ownership Overview
9.47% Insiders
15.60% Mutual Funds
8.01% Other Institutional Investors
62.41% Public Companies and
Individual Investors